Allogeneic hematopoietic stem cell transplantation in children with sickle cell disease.
Locatelli, Franco MD 1,2,*; Pagliara, Daria MD 1
[Review]
Pediatric Blood & Cancer.
59(2):372-376, August 2012.
(Format: HTML, PDF)
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents the only curative treatment for sickle cell disease (SCD), being successful in around 85-90% of patients. Mortality and long-term morbidity (including infertility, gonadal failure, and chronic graft-vs.-host disease) associated with conventional approaches curtail the number of patients who undergo allo-HSCT. Recently, it has been demonstrated that cord blood is as effective as and possibly safer than bone marrow in pediatric patients with SCD. Likewise, transplant strategies based on the use of reduced-intensity regimens and the induction of mixed chimerism have been explored to decrease allo-HSCT short- and long-term complications. Pediatr Blood Cancer 2012;59:372-376. (C) 2012 Wiley Periodicals, Inc.
Copyright (C) 2012 John Wiley & Sons, Inc.